X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
QN-302 is a small molecule G-Quadruplex (G4)-selective transcription inhibitor in Phase 1 clinical development for the treatment of G4-expressing solid tumors, such as pancreatic cancer (PDAC), prostate cancer, sarcomas, and others.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
QN-302 (formerly SOP1812) is a G4 selective transcription inhibitor. QN-302 is a small molecule drug candidate with superior efficacy and activity against pancreatic cancer.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
QN-302 is Qualigen’s G-quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for Pancreatic ductal adenocarcinoma (PDAC), in addition to other tumors of high unmet clinical need, such as Prostate Cancer.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hande Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 06, 2022
Details:
QN-302 is Qualigen’s G-quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for PDAC, in addition to other tumors of high unmet clinical need.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
QN-302, genomic quadruplex (G4)-selective transcription inhibitor demonstrated potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo model of metastatic prostate cancer.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
QN-302 is Qualigen’s genomic quadruplex (G4)-selective transcription inhibitor platform with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing G4s against “unwinding,” help inhibit cancer cell proliferation.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
QN-302 is the Company’s genomic quadruplex (G4)-selective transcription inhibitor being developed as a potential treatment for pancreatic ductal adenocarcinoma (PDAC), in addition to other tumors of high unmet clinical need.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
QN-302, selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against unwinding help inhibit cancer cell proliferation.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
QN-302 is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells help inhibit cancer cell proliferation as a potential treatment for pancreatic ductal adenocarcinoma.
Lead Product(s): QN-302
Therapeutic Area: Oncology Product Name: QN-302
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: University College London
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
